Findings showed that 53.8% of patients treated with emapalumab achieved a complete response. The Food and Drug Administration (FDA) has approved Gamifant ® (emapalumab-lzsg) for the treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results